AstraZeneca PLC (ETR:ZEG)
130.05
+0.65 (0.50%)
Sep 19, 2025, 5:36 PM CET
AstraZeneca Employees
AstraZeneca had 94,300 employees as of December 31, 2024. The number of employees increased by 4,400 or 4.89% compared to the previous year.
Employees
94,300
Change (1Y)
4,400
Growth (1Y)
4.89%
Revenue / Employee
€510,187
Profits / Employee
€74,901
Market Cap
201.14B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Siemens Healthineers AG | 72,000 |
Merck KGaA | 59,020 |
Bayer Aktiengesellschaft | 91,864 |
Fresenius SE & Co. KGaA | 176,486 |
Sartorius Aktiengesellschaft | 13,528 |
Fresenius Medical Care AG | 111,513 |
Fielmann Group AG | 24,363 |
Carl Zeiss Meditec AG | 5,730 |
AstraZeneca News
- 2 days ago - CEO At Rigel Pharmaceuticals Acquires Company Stock Options Worth $388K - Benzinga
- 2 days ago - Raymond Furey At Rigel Pharmaceuticals Secures Company Stock Options: $90K Acquired - Benzinga
- 2 days ago - Lisa Rojkjaer Enhances Portfolio With Rigel Pharmaceuticals Stock Options: $90K Acquired - Benzinga
- 2 days ago - Significant Move: David Santos Invests $90K In Rigel Pharmaceuticals Stock Options - Benzinga
- 2 days ago - Dean Schorno Makes Strategic Play: Invests $90K In Rigel Pharmaceuticals Stock Options - Benzinga
- 2 days ago - AstraZeneca (AZN) Reinforces Airsupra Benefits with New Clinical Data - GuruFocus
- 2 days ago - AstraZeneca : AIRSUPRA Gains FDA Label Update After Strong Results In Mild Asthma Patients - Nasdaq
- 2 days ago - Irelands pharma sector is world class, but why dont we have a Novo Nordisk to take our success to the next level? - Independent Ireland